Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Hemostatic profile of infants with spontaneous prematurity: can we predict intraventricular hemorrhage development?

Hochart A, Nuytten A, Pierache A, Bauters A, Rauch A, Wibaut B, Susen S, Goudemand J.

Ital J Pediatr. 2019 Aug 28;45(1):113. doi: 10.1186/s13052-019-0709-8.

2.

Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP).

Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, Rauch A, Roullet S, Fontana P, Goudemand J, de Maistre E, Chamouard V, Wibaut B, Albaladejo P, Négrier C.

Haemophilia. 2019 Sep;25(5):731-737. doi: 10.1111/hae.13817. Epub 2019 Jul 11. Review.

PMID:
31294904
3.

Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.

Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg M, Keller-Stanislawski B.

Haemophilia. 2019 May;25(3):398-407. doi: 10.1111/hae.13747. Epub 2019 May 7.

PMID:
31066174
4.

Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.

Dupont A, Soukaseum C, Cheptou M, Adam F, Nipoti T, Lourenco-Rodrigues MD, Legendre P, Proulle V, Rauch A, Kawecki C, Bryckaert M, Rosa JP, Paris C, Ternisien C, Boisseau P, Goudemand J, Borgel D, Lasne D, Maurice P, Lenting PJ, Denis CV, Susen S, Kauskot A.

Haematologica. 2019 Feb 28. pii: haematol.2018.206250. doi: 10.3324/haematol.2018.206250. [Epub ahead of print]

5.

FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders.

Doncarli A, Demiguel V, Guseva Canu I, Goulet V, Bayart S, Calvez T, Castet S, Dalibard V, Demay Y, Frotscher B, Goudemand J, Lambert T, Milien V, Oudot C, Sannié T, Chambost H; FranceCoag Network.

Eur J Epidemiol. 2019 May;34(5):521-532. doi: 10.1007/s10654-018-0468-7. Epub 2018 Dec 5.

PMID:
30515664
6.

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.

BMJ Open. 2018 Jul 25;8(7):e022409. doi: 10.1136/bmjopen-2018-022409.

7.

The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC, Lillicrap D, Hampshire DJ; European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups.

Blood Adv. 2018 Jul 10;2(13):1585-1594. doi: 10.1182/bloodadvances.2017011643.

8.

Fifth Åland Island conference on von Willebrand disease.

Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, Federici AB, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J.

Haemophilia. 2018 May;24 Suppl 4:5-19. doi: 10.1111/hae.13475.

PMID:
29687935
9.

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators.

Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.

10.

New findings on inhibitor development: from registries to clinical studies.

Peyvandi F, Ettingshausen CE, Goudemand J, Jiménez-Yuste V, Santagostino E, Makris M.

Haemophilia. 2017 Jan;23 Suppl 1:4-13. doi: 10.1111/hae.13137. Review.

PMID:
27990784
11.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

12.

Key insights to understand the immunogenicity of FVIII products.

Goudemand J, Peyvandi F, Lacroix-Desmazes S.

Thromb Haemost. 2016 Aug 31;116 Suppl 1:S2-9. doi: 10.1160/TH16-01-0048. Epub 2016 Aug 16.

PMID:
27528279
13.

Response to Wiewel-Verschueren S et al.: gynaecological and obstetrical bleeding in women with factor XI deficiency - a systematic review.

de Raucourt E, Bauduer F, Goudemand J.

Haemophilia. 2016 Sep;22(5):e435-6. doi: 10.1111/hae.13036. Epub 2016 Aug 3. No abstract available.

PMID:
27486008
14.

Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement.

Van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J, Jeanpierre E, Levade M, Hurt C, Rousse N, Dally JB, Debry N, Dallongeville J, Vincentelli A, Delhaye C, Auffray JL, Juthier F, Schurtz G, Lemesle G, Caspar T, Morel O, Dumonteil N, Duhamel A, Paris C, Dupont-Prado A, Legendre P, Mouquet F, Marchant B, Hermoire S, Corseaux D, Moussa K, Manchuelle A, Bauchart JJ, Loobuyck V, Caron C, Zawadzki C, Leroy F, Bodart JC, Staels B, Goudemand J, Lenting PJ, Susen S.

N Engl J Med. 2016 Jul 28;375(4):335-44. doi: 10.1056/NEJMoa1505643.

15.

Characterization of a novel large deletion caused by double-stranded breaks in 6-bp microhomologous sequences of intron 11 and 12 of the F13A1 gene.

Thomas A, Ivaškevičius V, Zawadzki C, Goudemand J, Biswas A, Oldenburg J.

Hum Genome Var. 2016 Feb 11;3:15059. doi: 10.1038/hgv.2015.59. eCollection 2016.

16.

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, Zawadzki C, Trossaert M, Itzhar-Baïkian N, Dreyfus M, d'Oiron R, Borel-Derlon A, Susen S, Bezieau S, Denis CV, Goudemand J; French Reference Center for von Willebrand disease.

Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.

17.

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.

Rauch A, Caron C, Vincent F, Jeanpierre E, Ternisien C, Boisseau P, Zawadzki C, Fressinaud E, Borel-Derlon A, Hermoire S, Paris C, Lavenu-Bombled C, Veyradier A, Ung A, Vincentelli A, van Belle E, Lenting PJ, Goudemand J, Susen S.

Thromb Haemost. 2016 May 2;115(5):950-9. doi: 10.1160/TH15-08-0638. Epub 2016 Jan 21.

PMID:
26791163
18.

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product.

Calvez T, Chambost H, Lutz P, Rothschild C, Goudemand J.

Blood. 2015 Jun 11;125(24):3817-9. doi: 10.1182/blood-2015-02-622167. No abstract available.

PMID:
26069335
19.

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.

Bauduer F, de Raucourt E, Boyer-Neumann C, Trossaert M, Beurrier P, Faradji A, Peynet J, Borg JY, Chamouni P, Chatelanaz C, Henriet C, Bridey F, Goudemand J; French Postmarketing Study Group.

Haemophilia. 2015 Jul;21(4):481-9. doi: 10.1111/hae.12655. Epub 2015 Mar 26.

20.

Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.

Nurden AT, Pillois X, Fiore M, Alessi MC, Bonduel M, Dreyfus M, Goudemand J, Gruel Y, Benabdallah-Guerida S, Latger-Cannard V, Négrier C, Nugent D, Oiron RD, Rand ML, Sié P, Trossaert M, Alberio L, Martins N, Sirvain-Trukniewicz P, Couloux A, Canault M, Fronthroth JP, Fretigny M, Nurden P, Heilig R, Vinciguerra C.

Hum Mutat. 2015 May;36(5):548-61. doi: 10.1002/humu.22776.

21.

Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions.

Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, Hurt C, Banfi C, Rousse N, Godier A, Caron C, Elkalioubie A, Corseaux D, Dupont A, Zawadzki C, Delhaye C, Mouquet F, Schurtz G, Deplanque D, Chinetti G, Staels B, Goudemand J, Jude B, Lenting PJ, Susen S.

Circ Res. 2015 Mar 27;116(7):1193-201. doi: 10.1161/CIRCRESAHA.116.305046. Epub 2015 Feb 10.

PMID:
25670067
22.

EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.

Polack B, Calvez T, Chambost H, Rothschild C, Goudemand J, Claeyssens S, Borel-Derlon A, Bardoulat I, Maurel F, Woronoff-Lemsi MC; EQOFIX Study Group.

Transfusion. 2015 Jul;55(7):1787-97. doi: 10.1111/trf.13016. Epub 2015 Feb 5.

PMID:
25652955
23.

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Calvez T, Chambost H, Claeyssens-Donadel S, d'Oiron R, Goulet V, Guillet B, Héritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J; FranceCoag Network.

Blood. 2014 Nov 27;124(23):3398-408. doi: 10.1182/blood-2014-07-586347. Epub 2014 Sep 24.

PMID:
25253771
24.

Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

Rauch A, Legendre P, Christophe OD, Goudemand J, van Belle E, Vincentelli A, Denis CV, Susen S, Lenting PJ.

Thromb Haemost. 2014 Nov;112(5):1014-23. doi: 10.1160/TH14-02-0148. Epub 2014 Jul 17.

PMID:
25030452
25.

FXI concentrate use and risk of thrombosis.

Bolton-Maggs P, Goudemand J, Hermans C, Makris M, de Moerloose P.

Haemophilia. 2014 Jul;20(4):e349-51. doi: 10.1111/hae.12457. Epub 2014 May 2. No abstract available.

PMID:
24785157
26.

Colonoscopy in patients with haemophilia: the duration of clotting factor coverage must be adjusted to suit the procedure.

Tintillier V, Branche J, Maunoury V, Goudemand J, Renom P.

Haemophilia. 2013 Sep;19(5):e296-8. doi: 10.1111/hae.12174. Epub 2013 May 15. No abstract available.

PMID:
23672809
27.

Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry.

Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, Lévesque H; SACHA Study Group.

Haemophilia. 2013 Jul;19(4):564-70. doi: 10.1111/hae.12138. Epub 2013 Apr 10.

PMID:
23574453
28.

VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group.

Blood. 2013 Mar 21;121(12):2336-9. doi: 10.1182/blood-2012-09-455089. Epub 2013 Jan 24.

29.

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

Legendre P, Navarrete AM, Rayes J, Casari C, Boisseau P, Ternisien C, Caron C, Fressinaud E, Goudemand J, Veyradier A, Denis CV, Lenting PJ, Christophe OD.

Blood. 2013 Mar 14;121(11):2135-43. doi: 10.1182/blood-2012-09-456038. Epub 2013 Jan 18.

PMID:
23335371
30.

Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.

Hivert B, Caron C, Petit S, Charpy C, Fankam-Siaka C, Lecocq S, Zawadzki C, Susen S, Rusu M, Duhamel A, Tournilhac O, Goudemand J, Morel P.

Blood. 2012 Oct 18;120(16):3214-21. doi: 10.1182/blood-2011-11-388256. Epub 2012 Aug 14.

PMID:
22896002
31.

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).

Tiede A, Friedrich U, Stenmo C, Allen G, Giangrande P, Goudemand J, Hay C, Holmström M, Klamroth R, Lethagen S, McKenzie S, Miesbach W, Negrier C, Yuste VJ, Berntorp E.

J Thromb Haemost. 2011 Jun;9(6):1191-9. doi: 10.1111/j.1538-7836.2011.04293.x.

33.

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.

Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J.

Haemophilia. 2011 Nov;17(6):944-51. doi: 10.1111/j.1365-2516.2011.02499.x. Epub 2011 Mar 3.

PMID:
21371195
34.

A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease.

Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I.

Haemophilia. 2011 Jan;17(1):165-6. doi: 10.1111/j.1365-2516.2010.02381.x. No abstract available.

PMID:
21199188
35.

Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort.

Hampshire DJ, Burghel GJ, Goudemand J, Bouvet LC, Eikenboom JC, Schneppenheim R, Budde U, Peake IR, Goodeve AC; EU-VWD and ZPMCB-VWD study groups.

Haematologica. 2010 Dec;95(12):2163-5. doi: 10.3324/haematol.2010.027177. Epub 2010 Sep 17. No abstract available.

36.

The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD.

Castaman G, Tosetto A, Goodeve A, Federici AB, Lethagen S, Budde U, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Habart D, Hill F, Peake I, Rodeghiero F.

Br J Haematol. 2010 Nov;151(3):245-51. doi: 10.1111/j.1365-2141.2010.08333.x. Epub 2010 Aug 25.

PMID:
20738304
37.

Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease.

Trossaërt M, Ternisien C, Lefrancois A, Llopis L, Goudemand J, Sigaud M, Fouassier M, Caron C.

Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E25-9. doi: 10.1177/1076029610379848. Epub 2010 Aug 19.

PMID:
20724302
38.

Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.

Castaman G, Tosetto A, Cappelletti A, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom JC, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill F, Peake IR, Rodeghiero F.

Thromb Res. 2010 Sep;126(3):227-31. doi: 10.1016/j.thromres.2010.06.013. Epub 2010 Jul 22.

PMID:
20650506
39.

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.

Oldenburg J, Goudemand J, Valentino L, Richards M, Luu H, Kriukov A, Gajek H, Spotts G, Ewenstein B.

Haemophilia. 2010 Nov;16(6):866-77. doi: 10.1111/j.1365-2516.2010.02332.x.

PMID:
20579113
40.

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.

Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici AB, James P, Peake I, Eikenboom J, Goodeve A; MCMDM-1VWD and ZPMCB-VWD study groups.

J Thromb Haemost. 2010 Sep;8(9):1986-93. doi: 10.1111/j.1538-7836.2010.03927.x.

41.

Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.

Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, Schramm W, Kirchmaier C, Martinowitz U.

Thromb Haemost. 2010 Feb;103(2):351-9. doi: 10.1160/TH09-04-0212. Epub 2009 Dec 18.

PMID:
20024491
42.

AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function.

Jallu V, Dusseaux M, Panzer S, Torchet MF, Hezard N, Goudemand J, de Brevern AG, Kaplan C.

Hum Mutat. 2010 Mar;31(3):237-46. doi: 10.1002/humu.21179.

43.

Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system.

El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, de Melo L, Soulié V, Adam J, Burnouf T.

Transfus Med. 2010 Feb;20(1):48-61. doi: 10.1111/j.1365-3148.2009.00963.x. Epub 2009 Sep 23.

PMID:
19778318
44.

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W, Mazurier C, Meyer D, Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A.

J Thromb Haemost. 2009 Aug;7(8):1304-12. doi: 10.1111/j.1538-7836.2009.03486.x. Epub 2009 Jun 30.

45.

Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population.

Lambert M, Ferrard-Sasson G, Dubucquoi S, Hachulla E, Prin L, Hatron PY, Goudemand J, Boffa MC, Caron C.

Thromb Haemost. 2009 Mar;101(3):577-81.

PMID:
19277423
46.

Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction.

Le Tourneau T, Susen S, Caron C, Millaire A, Maréchaux S, Polge AS, Vincentelli A, Mouquet F, Ennezat PV, Lamblin N, de Groote P, Van Belle E, Deklunder G, Goudemand J, Bauters C, Jude B.

Circulation. 2008 Oct 7;118(15):1550-7. doi: 10.1161/CIRCULATIONAHA.108.786681. Epub 2008 Sep 22.

PMID:
18809794
47.

Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate.

Négrier C, Rothschild C, Goudemand J, Borg JY, Claeyssens S, Alessi MC, Jaffry AC, Teboul C, Padrazzi B, Waegemans T.

J Thromb Haemost. 2008 Sep;6(9):1494-9. doi: 10.1111/j.1538-7836.2008.03076.x. Epub 2008 Jul 9.

48.

von Willebrand disease update: diagnostic and treatment dilemmas.

Bolton-Maggs PH, Lillicrap D, Goudemand J, Berntorp E.

Haemophilia. 2008 Jul;14 Suppl 3:56-61. doi: 10.1111/j.1365-2516.2008.01713.x.

PMID:
18510523
49.

Haemophilic arthropathy from A to Z. Introduction.

Négrier C, Goudemand J, Lambert T.

Haemophilia. 2008 Jul;14 Suppl 4:1-2. doi: 10.1111/j.1365-2516.2008.01731.x. No abstract available.

PMID:
18494685
50.

Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems.

Burnouf T, Caron C, Radosevich M, Goubran HA, Goudemand J, El-Ekiaby M.

Haemophilia. 2008 Sep;14(5):956-62. doi: 10.1111/j.1365-2516.2008.01797.x. Epub 2008 Jun 28.

PMID:
18565126

Supplemental Content

Loading ...
Support Center